Brief Articles
J ournal of Medicinal Chemistry, 1999, Vol. 42, No. 8 1479
1H NMR (DMSO-d6) 1.05-1.80 (m, 18H), 1.81-2.05 (bs, 2H),
2.06-2.40 (m, 4H), 2.70-2.95 (bs, 2H); 13C NMR (DMSO-d6)
22.19, 23.00, 24.25, 27.16, 29.64, 32.06, 42.58, 109.51, 174.89.
Anal. (C18H28O8) C, H.
1,10-Bis(ben zoyloxym eth yl)-7,8,15,16-tetr a oxa d isp ir o-
[5.2.5.2]h exa d eca n e (3i): yield 10%; mp 195 °C dec (ether:
pentane, 1:1); 1H NMR 1.15-2.01 (m, 14H), 2.04-2.32 (bs, 2H),
2.90-3.25 (bs, 2H), 4.10-4.49 (bs, 2H), 4.50-4.80 (bs, 2H),
7.30-7.75 (m, 6H), 7.90-8.30 (m, 4H); 13C NMR 22.03, 24.55,
25.72, 30.04, 43.30, 62.90, 109.13, 128.32, 129.56, 130.10,
132.92, 166.42. Anal. (C28H32O8) C, H.
1,10-Bis(m et h oxym et h yl)-7,8,15,16-t et r a oxa d isp ir o-
[5.2.5.2]h exa d eca n e (3j): yield 8%; mp 117-118 °C; 1H NMR
1.10-2.05 (m, 16H), 2.75-3.00 (bs, 2H), 3.32 (s, 6H), 3.15-
3.40 (m, 2H), 3.55-3.80 (m, 2H); 13C NMR 22.17, 24.38, 25.84,
29.90, 43.91, 58.84, 70.36, 109.14. Anal. (C16H28O6) C, H.
1,10-Bis(b en zyloxym et h yl)-7,8,15,16-t et r a oxa d isp ir o-
[5.2.5.2]h exa d eca n e (3k ): yield 10%; mp 131 °C (pentane);
1H NMR 1.20-1.82 (m, 12H), 1.85-2.10 (bs, 4H), 2.70-3.00
(bs, 2H), 3.20-3.55 (bs, 2H), 3.60-3.95 (bs, 2H), 4.30-4.70 (m,
4H), 7.15-7.50 (m, 10H); 13C NMR 22.17, 24.39, 26.02, 29.93,
44.06, 68.22, 73.14, 109.18, 127.52, 127.54, 128.32, 138.35.
Anal. (C28H36O6) C, H.
P r oced u r e for P r ep a r a tion of 3g a n d 3h . A mixture of
diester tetraoxane 3e or 3i (1 mmol), dichloromethane (1 mL),
MeOH (10 mL), and KOH (6 mmol, 0.35 g) dissolved in water
(1 mL) was heated to 70 °C for 1 h. Diacid tetraoxane 3g was
obtained by adding concentrated HCl (1 mL) to the cooled
reaction mixture followed by filtration and recrystallization
from DMSO. Tetraoxane diol 3h was obtained by adding water
(20 mL) to the cooled reaction mixture followed by filtration
and recrystallization from MeOH. Tetraoxanes 3g and 3h were
isolated as white crystalline solids.
1,10-Bis(ca r b oxym e t h yl)-7,8,15,16-t e t r a oxa d isp ir o-
[5.2.5.2]h exa d eca n e (3g): yield 72%; mp 198-199 °C dec;
1H NMR (DMSO-d6) 1.10-1.80 (m, 14H), 1.90-2.25 (m, 4H),
2.00-2.20 (m, 2H), 2.75-3.00 (bs, 2H); 13C NMR (DMSO-d6,
30 °C) 21.72, 23.89, 27.96, 29.07, 32.79, 39.68, 108.44, 172.88.
Anal. (C16H24O8) C, H.
1,10-Bis(h yd r oxym e t h yl)-7,8,15,16-t e t r a oxa d isp ir o-
[5.2.5.2]h exa d eca n e (3h ): yield 60%; mp 182 °C dec; 1H
NMR (DMSO-d6) 1.05-2.10 (m, 16H), 2.56-2.89 (bs, 2H),
3.05-3.32 (m, 2H), 3.60-3.89 (m, 2H), 4.54 (t, J ) 5.3 Hz, 2H);
13C NMR (DMSO-d6) 21.93, 23.62, 25.13, 29.19, 45.85, 58.34,
108.99. Anal. C14H24O6: C, H.
An tim alar ial Scr een s. In vitro antimalarial activity against
the drug-sensitive NF54 and chloroquine-resistant K1 strains
of P. falciparum was determined by a modified tritiated
hypoxanthine uptake method of Desjardins et al.13 as previ-
ously described in detail.14 Data were expressed as IC50 values,
estimated as described by Huber and Koella.15 In vivo anti-
malarial activity was assessed using Moro SPF mice infected
with the ANKA strain of P. berghei as described by Ridley et
al.14 Groups of three mice were treated on day 1 post-infection
with tetraoxanes dissolved or suspended in 3% ethanol and
7% Tween 80. Tetraoxanes were administered as single 100
mg/kg doses sc and po. Antimalarial activity was measured
by percent reduction in parasitemia on day 3 post-infection
and by survival times compared to an untreated control group.
limitation, incorporation of unsaturated and polar func-
tional groups at other positions in dispiro-1,2,4,5-
tetraoxanes is possible, and this work provides a guide
to functional group selection in the search for more
orally active tetraoxane antimalarials.
Exp er im en ta l Section
Melting points are uncorrected. Unless noted otherwise, 1H
(300 MHz) and 13C (75 MHz) NMR spectra were recorded on
a Varian XL-300 spectrometer using CDCl3 as a solvent. All
chemical shifts are reported in parts per million (ppm) and
are relative to internal (CH3)4Si for 1H and CDCl3 (77.0 ppm)
for 13C NMR. Microanalyses were performed by M-H-W-
laboratories, Phoenix, AZ. 2-Allyl- and 2-carboethoxymethyl-
cyclohexanone were purcased from Aldrich Chemical Co.
2-Benzyl-, 2-propargyl-, 2-carboethoxyethyl-, and 2-benzyl-
oxymethylcyclohexanone were prepared by enamine alkylation
reactions described by Stork et al.11 2-Hydroxymethylcyclo-
hexanone was prepared from cyclohexanone and paraform-
aldehyde.12 2-Benzoyloxymethylcyclohexanone was synthe-
sized by acylation of 2-hydroxymethylcyclohexanone with
benzoyl chloride in pyridine/dichloromethane. 2-Carboxyethyl-
and 2-carboxymethylcyclohexanone were prepared by hydroly-
sis of the corresponding commercially available ethyl esters
in KOH/MeOH followed by acidification using concentrated
HCl.
Gen er a l P r oced u r e8 for t h e P r ep a r a t ion of Tet r a -
oxa n es 3a -3f a n d 3i-3k . A cold (-20 °C) solution of a parent
cyclohexanone (10 mmol) in acetonitrile (2 mL) was added
dropwise to a stirred, cold (-30 °C) solution of 50% hydrogen
peroxide (0.60 mL, 11 mmol) and concentrated sulfuric acid
(1 mL) in acetonitrile (4 mL). After being stirred for an
additional 1 h at -30 to -20 °C, the solution was kept at -20
°C for 2 days. If the required product precipitated or crystal-
lized out of the reaction solvent (3a , 3c, 3e, 3f, 3i, 3k ), a simple
filtration and recrystallization sufficed for purification. If the
product tetraoxane did not precipitate (3b, 3d , 3j), extraction
with dichloromethane and subsequent silica gel flash column
chromatography eluting with petroleum ether/ether (9:1) were
applied to isolate the product. In each case, product tetra-
oxanes were isolated as white crystalline solids.
1,10-Bis(2-p r op en yl)-7,8,15,16-tetr a oxa d isp ir o[5.2.5.2]-
h exa d eca n e (3a ): yield 5%; mp 101-102 °C (CH3CN); 1H
NMR 1.05-1.45 (m, 4H), 1.46-1.82 (m, 12H), 1.85-2.15 (m,
2H), 2.40-2.70 (m, 2H), 2.80-3.10 (m, 2H), 4.90-5.17 (m, 4H),
5.55-5.90 (m, 2H); 13C NMR 22.31, 24.54, 27.01, 29.91, 32.06,
43.27, 109.28, 116.46, 136.84. Anal. (C18H28O4) C, H.
1,10-Bis(2-p r op yn yl)-7,8,15,16-tetr a oxa d isp ir o[5.2.5.2]-
h exa d eca n e (3b): yield 10%; mp 167-168 °C dec (CH3CN);
1H NMR 1.15-2.40 (m, 20H), 2.50-2.79 (m, 2H), 2.80-3.04
(bs, 2H); 13C NMR 17.54, 22.18, 24.59, 27.19, 29.83, 42.97,
69.44, 82.51, 108.67. Anal. (C18H24O4) C, H.
1,10-Dib en zyl-7,8,15,16-t et r a oxa d isp ir o[5.2.5.2]h exa -
d eca n e (3c): yield 13%; mp 182-184 °C dec (CH3CN); 1H
NMR 1.10-1.42 (m, 4H), 1.48-1.78 (m, 10H), 1.82-1.98 (m,
2H), 2.34-2.53 (m, 2H), 3.03-3.19 (m, 2H), 3.20-3.37 (m, 2H),
7.09-7.37 (m, 10H); 13C NMR 22.36, 24.61, 26.66, 30.08, 33.71,
45.65, 109.31, 125.99, 128.29, 129.21, 140.24. Anal. (C26H32O4)
C, H.
Ack n ow led gm en t. We gratefully acknowledge the
expert technical assistance of Ms. A. Luginbu¨hl with the
vitro and vivo antimalarial assays. This investigation
received financial support from the UNDP/WORLD
BANK/WHO Special Program for Research and Train-
ing in Tropical Diseases (TDR ID No. 960275) and
DHHS/NIH/NIAID (R15 AI39670-01).
1,10-Bis(ca r boeth oxyeth yl)-7,8,15,16-tetr a oxa d isp ir o-
[5.2.5.2]h exa d eca n e (3d ): yield 9%; mp 87 °C; 1H NMR 1.26
(t, J ) 7.2 Hz, 6H), 1.20-1.85 (m, 18H), 1.90-2.50 (m, 6H),
2.80-3.15 (bs, 2H), 4.13 (q, J ) 7.1 Hz, 4H); 13C NMR 14.17,
23.08, 24.39, 27.31, 29.64, 29.72, 32.59, 42.91, 60.24, 109.55,
173.40. Anal. (C22H36O8) C, H.
1,10-Bis(car boeth oxym eth yl)-7,8,15,16-tetr aoxadispir o-
[5.2.5.2]h exa d eca n e (3e): yield 4%; mp 110 °C (pentane);
1H NMR 1.26 (t, J ) 7.1 Hz, 6H), 1.20-1.85 (m, 14H), 2.05-
2.40 (m, 4H), 2.70-2.89 (m, 2H), 2.90-3.12 (bs, 2H), 4.13 (q,
J ) 7.1 Hz, 4H); 13C NMR 14.18, 22.17, 24.70, 28.36, 29.89,
33.34, 40.33, 60.50, 108.80, 172.38. Anal. (C20H32O8) C, H.
1,10-Bis(car boxyeth yl)-7,8,15,16-tetr aoxadispir o[5.2.5.2]-
h exa d eca n e (3f): yield 12%; mp 178 °C (CH3OH:H2O, 1:1);
Refer en ces
(1) For recent reviews, see: (a) J efford, C. W. Peroxidic Antima-
larials. Adv. Drug Res. 1997, 29, 271-325. (b) Casteel, D. A.
Antimalarial Agents. In Burger’s Medicinal Chemistry and Drug
Discovery; Wolff, M. E., Ed.; J ohn Wiley & Sons: New York,
1997; Vol. 5, pp 3-91. (c) Cumming, J . N.; Ploypradith, P.;